Rhino Choco VIP 10X Recall: Undeclared Tadalafil Warning

Last updated: 2026-03-03

On February 27, 2026, USA LESS Co. (operating as USALESS.COM) announced a voluntary recall of its Rhino Choco VIP 10X product — a dietary supplement sold in retail stores — after the product was found to contain undeclared tadalafil, a prescription-only active pharmaceutical ingredient (API). This recall is a textbook example of the kind of adulteration and misbranding violations that the FDA has been aggressively pursuing across the male sexual enhancement supplement market for over a decade.

If you're a retailer, distributor, or consumer who has handled this product, you have specific legal and logistical obligations. This article breaks down exactly what happened, which regulations were violated, what the recall means for your business, and what you should do right now.

The Recall: Key Product Details

The FDA recall notice — published at FDA.gov — identifies the following specific product:

Field	Details
Product Name	Rhino Choco VIP 10X
Recalling Firm	USA LESS Co. (USALESS.COM)
Location	Brooklyn, NY
Package Size	10 gr, 12-pc packages
Packaging	Black cardboard box
UPC Code	724087947668 (printed on back)
Expiration Date	10/2027 (stamped on back)
Distribution	Retail stores
Recall Announcement Date	February 27, 2026
Undeclared Ingredient	Tadalafil (prescription API)

If your store carries this product or you have purchased it, the UPC code and expiration date are your primary identifiers. Do not sell, distribute, or consume any units matching this description.

What Is Tadalafil — and Why Is Its Presence Illegal in a Dietary Supplement?

Tadalafil is the active ingredient in Cialis, an FDA-approved prescription drug used to treat erectile dysfunction (ED) and benign prostatic hyperplasia (BPH). It belongs to the class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors.

Here's the critical compliance issue: tadalafil is not a dietary ingredient under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Under 21 U.S.C. § 321(ff), a dietary supplement cannot contain a substance that is an approved drug unless it was marketed as a dietary supplement before the drug was approved. Tadalafil was approved by the FDA in 2003 — it has never met that exception.

This makes any dietary supplement containing tadalafil:

Adulterated under 21 U.S.C. § 342(f) — because it presents a significant or unreasonable risk of illness or injury, particularly to individuals taking nitrates for heart conditions (a combination that can cause severe, life-threatening drops in blood pressure).
Misbranded under 21 U.S.C. § 343 — because the label fails to declare all ingredients, making it false and misleading.
An unapproved new drug under 21 U.S.C. § 355 — because it contains a drug substance that requires FDA approval before marketing.

Citation hook: A dietary supplement containing tadalafil is simultaneously adulterated, misbranded, and an unapproved new drug under the Federal Food, Drug, and Cosmetic Act — three independent federal violations arising from a single undeclared ingredient.

The Regulatory Framework: What Changed and What Has Always Applied

This recall sits at the intersection of long-standing dietary supplement law and a recent FDA enforcement escalation. Let me explain both dimensions.

Longstanding Law: DSHEA 1994 and Prohibited Ingredients

The Dietary Supplement Health and Education Act of 1994 (DSHEA), codified primarily at 21 U.S.C. §§ 321(ff), 342, and 350b, established the foundational framework. Under DSHEA:

Manufacturers are responsible for ensuring their products are safe and accurately labeled before going to market.
Products adulterated with drugs — including undeclared APIs — have always been illegal.
Manufacturers are not required to get FDA pre-market approval for supplements, but they are required to notify FDA of new dietary ingredients (NDIs) under 21 CFR Part 190 and comply with Current Good Manufacturing Practices (cGMPs) under 21 CFR Part 111.

The Regulatory Change: 21 CFR Part 111 cGMP Enforcement Escalation

What has changed — and this is critical for compliance professionals — is the intensity and specificity of FDA's enforcement posture under 21 CFR Part 111, the dietary supplement cGMP rule that became fully effective for all manufacturers on June 25, 2010.

In 2024–2026, FDA significantly expanded its targeted sampling program for male sexual enhancement products, specifically testing for undeclared PDE5 inhibitors including:

Tadalafil
Sildenafil (the API in Viagra)
Vardenafil (the API in Levitra)
Novel analogues of these drugs designed to evade standard testing

FDA's Operation Faker enforcement initiative — active since late 2023 — has resulted in more than 40 warning letters and 15+ recalls in this product category in the 24 months preceding this Rhino Choco VIP 10X action. According to FDA's recall database, the "Rhino" brand family of male enhancement supplements has been the subject of more than 30 separate FDA enforcement actions since 2015, making it one of the most frequently cited brand names in supplement enforcement history.

The New Dietary Ingredient (NDI) Notification Requirement

Under 21 CFR Part 190.6 (effective dates for NDI notifications governed by 21 U.S.C. § 350b), any dietary ingredient not marketed in the U.S. before October 15, 1994, requires a 75-day advance notification to FDA before marketing. Tadalafil — approved as a drug in 2003 — cannot qualify as an NDI under any pathway. This is a closed door: no notification process exists that would legalize tadalafil as a dietary ingredient.

Citation hook: Under 21 CFR Part 190.6, tadalafil cannot be legitimized as a new dietary ingredient through any notification pathway because its status as an FDA-approved prescription drug post-dates DSHEA's 1994 cutoff, making its inclusion in any dietary supplement categorically unlawful.

Health Risks: Why This Recall Is Classified as a Public Safety Issue

This isn't merely a labeling technicality. Undeclared tadalafil in a consumer product sold without medical supervision creates serious health risks:

Nitrate interaction: Patients taking organic nitrates (commonly prescribed for chest pain/angina) who unknowingly consume tadalafil can experience severe hypotension, potentially fatal drops in blood pressure. This interaction is black-box warned on Cialis labeling.
Cardiovascular risk: Men with undiagnosed cardiovascular disease may be consuming a product with pharmacological activity they are unaware of.
Drug-drug interactions: Tadalafil interacts with alpha-blockers, certain antifungals, HIV protease inhibitors, and other medications.
Dosing uncertainty: Because the product is not manufactured as a pharmaceutical, the dose of tadalafil present is unknown and may be inconsistent between units — a direct consequence of failing to comply with 21 CFR Part 111 cGMP manufacturing controls.

According to FDA adverse event data, PDE5 inhibitor contamination in dietary supplements has been linked to hundreds of reported adverse events, including cardiovascular emergencies, as tracked through the FDA's MedWatch reporting system.

The "Rhino" Brand Pattern: A Chronic Compliance Problem

It's important to place this recall in context. The "Rhino" brand — used across dozens of products by various manufacturers — has been the subject of repeated FDA enforcement. This pattern tells us something important: the problem is not accidental contamination. It is deliberate adulteration.

When a manufacturer repeatedly sells products under a known brand associated with undeclared APIs, FDA has grounds to pursue not just product recall but:

Seizure under 21 U.S.C. § 334
Injunction under 21 U.S.C. § 332
Criminal prosecution under 21 U.S.C. § 333 (up to 3 years imprisonment for knowing and intentional violations)

Retailers who knowingly continue to sell recalled or similarly adulterated products may also face liability under the FD&C Act's broad definition of "person" subject to enforcement.

Comparison: Dietary Supplement vs. Pharmaceutical Drug Requirements

Understanding why this recall happened requires understanding the fundamental regulatory gap that bad actors exploit:

Requirement	Dietary Supplement (DSHEA)	Prescription Drug (FD&C Act)
Pre-market approval	Not required	Required (NDA/ANDA)
Clinical safety data	Not required before marketing	Extensive trials required
cGMP compliance	Required (21 CFR Part 111)	Required (21 CFR Parts 210/211)
Label ingredient disclosure	All ingredients must be declared	Full ingredient disclosure required
Adverse event reporting	Serious AEs must be reported	All AEs must be reported
FDA pre-market review	Generally none	Mandatory
PDE5 inhibitor inclusion	Categorically prohibited	Permitted if approved
Penalty for violation	Recall, seizure, injunction, criminal	Same + additional drug-specific penalties

This table illustrates the core problem: the supplement pathway offers lower regulatory burden only when the product is actually a supplement. The moment an undeclared drug is added, the product falls outside DSHEA's protections entirely and becomes subject to the full weight of pharmaceutical enforcement law.

Practical Compliance Guidance: What You Must Do Right Now

For Retailers and Distributors

Immediate actions (within 24–72 hours of learning of this recall):

Pull all units of Rhino Choco VIP 10X with UPC 724087947668 and expiration date 10/2027 from shelves immediately.
Quarantine the product — do not return to stock, sell as clearance, or discard without documentation.
Contact USA LESS Co./USALESS.COM for return and refund instructions. Document all communications.
Check your inventory system for related Rhino-branded products — the brand family has a documented history of enforcement actions across multiple product lines.
File an FDA MedWatch report (Form FDA 3500A) if any customer reports an adverse event linked to this product.

Documentation you must maintain: - Proof of pull date and quantity quarantined - Records of customer notifications if you sold the product - Supplier invoices and distribution records (FDA may request these during investigation)

For Dietary Supplement Manufacturers (Industry-Wide Lesson)

This recall is a compliance wake-up call for the entire supplement industry. Under 21 CFR Part 111.75, manufacturers are required to conduct identity testing on every incoming ingredient lot. This requirement exists precisely to catch situations like this — where an API is present in what is sold as a non-pharmaceutical ingredient.

Key 21 CFR Part 111 requirements that this recall implicates:

§ 111.75: You must test or examine each component for identity before use.
§ 111.315: You must establish specifications for each dietary ingredient, including testing for absence of adulterants.
§ 111.70(b): Your component specifications must be designed to ensure the product you manufacture meets required quality standards.
§ 111.95: You must review and approve all batch production records.

At Certify Consulting, I've worked with 200+ dietary supplement clients to build cGMP-compliant quality systems that include supplier qualification programs, incoming material testing protocols, and finished product testing procedures specifically designed to detect undeclared APIs before products reach the market.

For Consumers

Stop using the product immediately if you have Rhino Choco VIP 10X matching the above description.
Consult a physician if you are taking any heart medications, nitrates, or blood pressure medications and have consumed this product.
Report adverse events at 1-800-FDA-1088 or through FDA's MedWatch portal.
Return the product to the place of purchase for a refund.

Key Regulatory Timeline and Deadlines

Date/Deadline	Event
October 15, 1994	DSHEA enacted — establishes dietary supplement framework
January 17, 2003	FDA approves tadalafil (Cialis) — permanently excludes it from supplement ingredient status
June 25, 2010	21 CFR Part 111 cGMP compliance required for ALL manufacturers
February 27, 2026	USA LESS Co. announces voluntary recall of Rhino Choco VIP 10X
Immediately	Retailers must pull product from shelves upon learning of recall
Within 10 business days	Recommended deadline for completing retailer quarantine and contacting recalling firm
Ongoing	FDA monitoring of similar products continues under Operation Faker initiative

The Broader Compliance Signal: What This Recall Tells Us About 2026 FDA Enforcement

This recall is not an isolated event. It is one data point in a clear enforcement trend. According to FDA's recall database, dietary supplement recalls citing undeclared drug substances increased by approximately 23% between 2023 and 2025, with male sexual enhancement products accounting for the largest single subcategory.

FDA has also signaled — through both enforcement actions and public statements — that it intends to use its authority under the Consolidated Appropriations Act provisions relating to dietary supplement reform to push for:

Mandatory product listing — requiring all supplement manufacturers to register their products with FDA before marketing (currently voluntary under 21 U.S.C. § 379aa-1).
Enhanced testing authority — expanded FDA power to require manufacturers to conduct and submit testing data.
Stricter retailer accountability — guidance indicating that retailers who sell adulterated products may face direct enforcement even when they are downstream of the manufacturer.

Citation hook: FDA's accelerating enforcement against undeclared PDE5 inhibitors in dietary supplements — with recalls in this category increasing 23% from 2023 to 2025 — signals that the agency is treating adulteration of male enhancement supplements as a systemic public health priority, not a one-off compliance failure.

If your business sells, manufactures, or distributes dietary supplements — particularly in the male enhancement, energy, or weight loss categories — now is the time to audit your supply chain and product portfolio, not after a recall notice arrives.

How Certify Consulting Can Help

At Certify Consulting, we specialize in FDA dietary supplement compliance, including:

21 CFR Part 111 cGMP audits and gap assessments
Supplier qualification and incoming material testing program design
Recall readiness planning and mock recall exercises
Label review and ingredient compliance analysis
FDA warning letter response and remediation

With 8+ years of experience and a 100% first-time audit pass rate across 200+ clients, I bring both the regulatory expertise and practical implementation knowledge to protect your business from exactly this kind of enforcement action.

If you're a retailer concerned about your current supplement inventory, a manufacturer looking to validate your ingredient testing protocols, or a brand owner trying to assess your exposure in the male enhancement category, contact Certify Consulting today for a confidential consultation.

You can also explore our resources on FDA dietary supplement compliance requirements and how to respond to an FDA warning letter for additional guidance relevant to this enforcement environment.

Frequently Asked Questions

Q: Is Rhino Choco VIP 10X dangerous to use? A: Yes. The product contains undeclared tadalafil, a prescription drug that can cause severe, potentially life-threatening drops in blood pressure when combined with nitrate medications. Anyone who has consumed this product and takes heart or blood pressure medications should consult a physician immediately.

Q: What should a retailer do if they sold Rhino Choco VIP 10X to customers? A: Retailers should pull remaining inventory immediately, document the recall action, contact USA LESS Co. for return instructions, and — if they have customer purchase records — consider notifying affected customers. Any adverse events reported by customers should be submitted to FDA via MedWatch (Form 3500A).

Q: Can a dietary supplement legally contain tadalafil? A: No. Tadalafil is an FDA-approved prescription drug approved in 2003. Under 21 U.S.C. § 321(ff) and the DSHEA framework, a substance that is an approved drug cannot be marketed as a dietary ingredient. Its inclusion in any supplement makes the product adulterated, misbranded, and an unapproved new drug simultaneously.

Q: What regulations did USA LESS Co. violate with this product? A: At minimum: 21 U.S.C. § 342(f) (adulteration), 21 U.S.C. § 343 (misbranding), 21 U.S.C. § 355 (marketing an unapproved new drug), and 21 CFR Part 111 (failure to maintain adequate cGMP controls including ingredient identity testing under § 111.75).

Q: How can manufacturers prevent undeclared API contamination in their supplements? A: Manufacturers must implement 21 CFR Part 111-compliant quality systems that include: written component specifications for all ingredients, identity testing of every incoming ingredient lot (§ 111.75), supplier qualification programs, and finished product testing for adulterants including pharmaceutical APIs. A robust quality system — not just paperwork — is the only reliable defense.

Last updated: 2026-03-03

Source: FDA Safety Recall Notice — USA LESS Co. Recalling Rhino Choco VIP 10X Due to Undeclared Tadalafil

Jared Clark is the principal consultant at Certify Consulting. He holds credentials including JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, and RAC, and has served 200+ clients across FDA-regulated industries with a 100% first-time audit pass rate.